Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Expression of UbcH10 in pancreatic ductal adenocarcinoma and its correlation with prognosis.

Zhao ZK, Wu WG, Chen L, Dong P, Gu J, Mu JS, Yang JH, Liu YB.

Tumour Biol. 2013 Jun;34(3):1473-7. doi: 10.1007/s13277-013-0671-9. Epub 2013 Jan 26.

PMID:
23355337
2.

Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance.

Xue YZ, Sheng YY, Liu ZL, Wei ZQ, Cao HY, Wu YM, Lu YF, Yu LH, Li JP, Li ZS.

Tumour Biol. 2013 Apr;34(2):895-9. doi: 10.1007/s13277-012-0624-8. Epub 2012 Dec 18.

PMID:
23247867
3.

High level of FOXC1 expression is associated with poor prognosis in pancreatic ductal adenocarcinoma.

Wang L, Gu F, Liu CY, Wang RJ, Li J, Xu JY.

Tumour Biol. 2013 Apr;34(2):853-8. doi: 10.1007/s13277-012-0617-7. Epub 2012 Dec 16.

PMID:
23242609
4.

MTA2 expression is a novel prognostic marker for pancreatic ductal adenocarcinoma.

Chen DW, Fan YF, Li J, Jiang XX.

Tumour Biol. 2013 Jun;34(3):1553-7. doi: 10.1007/s13277-013-0685-3. Epub 2013 Feb 12.

PMID:
23400716
5.

Overexpression of FOXM1 is associated with poor prognosis and clinicopathologic stage of pancreatic ductal adenocarcinoma.

Xia JT, Wang H, Liang LJ, Peng BG, Wu ZF, Chen LZ, Xue L, Li Z, Li W.

Pancreas. 2012 May;41(4):629-35. doi: 10.1097/MPA.0b013e31823bcef2.

PMID:
22249132
6.

DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma.

Xue YZ, Wu TL, Wu YM, Sheng YY, Wei ZQ, Lu YF, Yu LH, Li JP, Li ZS.

Tumour Biol. 2013 Oct;34(5):2857-61. doi: 10.1007/s13277-013-0846-4. Epub 2013 May 17.

PMID:
23681804
7.

Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.

Piao J, Liu S, Xu Y, Wang C, Lin Z, Qin Y, Liu S.

Exp Mol Pathol. 2015 Feb;98(1):1-6. doi: 10.1016/j.yexmp.2014.11.003. Epub 2014 Nov 5.

PMID:
25445504
8.

Prostate-specific membrane antigen as a marker of pancreatic cancer cells.

Ren H, Zhang H, Wang X, Liu J, Yuan Z, Hao J.

Med Oncol. 2014 Mar;31(3):857. doi: 10.1007/s12032-014-0857-z. Epub 2014 Jan 30.

PMID:
24477651
9.

CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma.

Wang L, Gu F, Ma N, Zhang L, Bian JM, Cao HY.

Tumour Biol. 2013 Aug;34(4):2309-13. doi: 10.1007/s13277-013-0775-2. Epub 2013 Apr 9.

PMID:
23568706
10.

Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.

Jin A, Xu Y, Liu S, Jin T, Li Z, Jin H, Lin L, Lin Z.

Exp Mol Pathol. 2014 Feb;96(1):54-60. doi: 10.1016/j.yexmp.2013.11.003. Epub 2013 Nov 18.

PMID:
24263054
11.

Expression of galectin-3 in pancreatic ductal adenocarcinoma.

Gaida MM, Bach ST, Günther F, Baseras B, Tschaharganeh DF, Welsch T, Felix K, Bergmann F, Hänsch GM, Wente MN.

Pathol Oncol Res. 2012 Apr;18(2):299-307. doi: 10.1007/s12253-011-9444-1. Epub 2011 Sep 12.

PMID:
21910036
12.

Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma.

Cui J, Yu Y, Lu GF, Liu C, Liu X, Xu YX, Zheng PY.

Tumour Biol. 2013 Jun;34(3):1913-8. doi: 10.1007/s13277-013-0735-x. Epub 2013 Mar 21.

PMID:
23516026
13.

Collapsin response mediator protein 4 expression is associated with liver metastasis and poor survival in pancreatic cancer.

Hiroshima Y, Nakamura F, Miyamoto H, Mori R, Taniguchi K, Matsuyama R, Akiyama H, Tanaka K, Ichikawa Y, Kato S, Kobayashi N, Kubota K, Nagashima Y, Goshima Y, Endo I.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S369-78. doi: 10.1245/s10434-012-2491-3. Epub 2012 Jul 18.

PMID:
22805864
14.

ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival.

Ni SS, Zhang J, Zhao WL, Dong XC, Wang JL.

Tumour Biol. 2013 Jun;34(3):1813-8. doi: 10.1007/s13277-013-0721-3. Epub 2013 Mar 9.

PMID:
23475633
15.

Low expression of IGFBP7 is associated with poor outcome of pancreatic ductal adenocarcinoma.

An W, Ben QW, Chen HT, Zheng JM, Huang L, Li GX, Li ZS.

Ann Surg Oncol. 2012 Nov;19(12):3971-8. doi: 10.1245/s10434-012-2407-2. Epub 2012 May 24.

PMID:
22622471
16.

Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer.

Fong D, Spizzo G, Mitterer M, Seeber A, Steurer M, Gastl G, Brosch I, Moser P.

Ann Surg Oncol. 2012 Dec;19(13):4330-6. doi: 10.1245/s10434-012-2381-8. Epub 2012 May 2.

PMID:
22549289
17.

Prognostic significance of XB130 expression in surgically resected pancreatic ductal adenocarcinoma.

Zhang J, Jiang X, Zhang J.

World J Surg Oncol. 2014 Mar 1;12:49. doi: 10.1186/1477-7819-12-49.

18.

Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.

Li H, Zhou RJ, Zhang GQ, Xu JP.

Tumour Biol. 2013 Jun;34(3):1807-12. doi: 10.1007/s13277-013-0720-4. Epub 2013 Mar 8.

PMID:
23471668
19.

UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer.

Zhao L, Jiang L, Wang L, He J, Yu H, Sun G, Chen J, Xiu Q, Li B.

J Cancer Res Clin Oncol. 2012 Nov;138(11):1951-61. doi: 10.1007/s00432-012-1275-2. Epub 2012 Jul 4.

PMID:
22760214
20.

Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.

Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H.

Mod Pathol. 2012 Jan;25(1):112-21. doi: 10.1038/modpathol.2011.142. Epub 2011 Oct 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk